Dr Jeremy Hing comes to us with over 15 years of pharmacometric and drug development experience, including 3 years consulting with Cognigen Corporation and several years working as a modeler with drug development teams at both Merck and Johnson & Johnson.
Jeremy was first introduced to the field of modeling as a graduate student, receiving his PhD in the use of NONMEM for the interpretation of preclinical studies in 2001, from the University of Newcastle-upon-Tyne (United Kingdom). He has experience in the use of PK and PK/PD in a wide range of therapeutic areas including oncology, cardiovascular, diabetes, neuroscience, asthma, and infectious diseases and has provided pharmacometric support for numerous regulatory submissions. Jeremy’s primary research interests include the application of optimality to enhance study design and novel covariate identification methods.
Outside of work, Jeremy enjoys running and has completed several marathons in recent years.